UT Southwestern researchers identify antibodies linked to kidney transplant rejection

September 26, 2007

DALLAS -- Sept. 27, 2007 -- UT Southwestern Medical Center researchers, collaborating with colleagues in Germany, have for the first time identified antibodies associated with transplant rejection of otherwise healthy kidneys.

For years, physicians have been perplexed as to why some seemingly well-matched kidneys were still rejected. The collaborative effort has turned up a likely culprit - antibodies that aren't targeted by current testing methods.

The research appears in today's edition of the New England Journal of Medicine, along with an accompanying editorial.

The antibodies in question attack a naturally occurring antigen called MICA, which is found in endothelial cells. The endothelium is the layer of cells lining the inside of the blood vessels. Each person has one or two of the more than 60 varieties of MICA antigens currently known.

"When you put a transplant in, the blood of the new host comes into contact first with the endothelium of the donor organ. That's where the host first meets the donor and where rejection starts," said Dr. Peter Stastny, professor of internal medicine, chief of transplant immunology and an author on the study.

"The bottom line is that the data suggests that failure of otherwise well-matched kidneys may be caused by these antibodies. We are not saying that all such kidneys fail because of antibodies against MICA, but this may be part of it," he said.

Dr. Stastny believes more research will be needed to show whether this is the direct cause, but the results offer critical direction in finding new explanations of why good transplants go bad and discovering potentially new avenues for screening to prevent rejection of transplanted kidneys.

Available kidneys remain in short supply, and more than 73,000 people await kidney transplants in the U.S., making successful transplants critical. Roughly 14,000 transplants were performed during the first half of 2007.

In Texas, about 600 kidney transplants have been performed this year. Between 89 percent and 95 percent of transplanted kidneys continue to function one year after the operation, according to the National Kidney Foundation.

UT Southwestern researchers became interested several years ago in the possibility that there might be some antigens in the kidney that were not present on lymphocytes, which are the cells used for typing and cross-matching for kidney transplants. Lymphocytes are white blood cells that carry out the body's immune response.

"If the antigens are not present on the lymphocytes, then the usual lymphocyte cross-match would not detect such antibodies," Dr. Stastny said.

Researchers first had to confirm that the antigens were present in the kidneys, then follow enough cases to determine whether the antibodies against MICA antigens correlated with rejection of otherwise healthy kidneys. For that, UT Southwestern investigators collaborated with researchers at the University of Heidelberg, which maintains a large depository of data and samples on transplant cases.

"They were able to provide a large number of samples - 1,910 - all taken before the transplant, so we were able to analyze them with our MICA antibody assay," Dr. Stastny said. "We found that there was a strong correlation. The presence of the antibodies against MICA was associated with earlier rejection of the kidney grafts.

"It doesn't prove that the antibody causes the rejection, but it suggests it." In addition, researchers discovered that the patients who were considered a good risk in clinical transplantation were the ones who showed the most marked effect of these antibodies against MICA.
Dr. Yizhou Zou, assistant professor of internal medicine at UT Southwestern, was the first author on the study.

This news release is available on our World Wide Web home page at http://www.utsouthwestern.edu/utsw/cda/dept353744/files/413352.html

To automatically receive news releases from UT Southwestern via e-mail, subscribe at www.utsouthwestern.edu/receivenews

Dr. Peter Stastny -- http://www.utsouthwestern.edu/findfac/professional/0,2356,16959,00.html

UT Southwestern Medical Center

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.